Skip to content

The biological basis of blood stasis in collaterals syndrome in posthepatitis B cirrhosis based on the relationship between intestinal flora and bile acid metabolism

The biological basis of blood stasis in collaterals syndrome in posthepatitis B cirrhosis based on the relationship between intestinal flora and bile acid metabolism

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024415
Enrollment
Unknown
Registered
2019-07-10
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posthepatitis B cirrhosis

Interventions

group of blood stasis and collateral obstruction syndrome in posthepatitis B cirrhosis:none
group of non-blood stasis and collateral obstruction syndrome in posthepatitis B cirrhosis:none
healthy control group:none

Sponsors

Tianjin Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 72 Years

Inclusion criteria

Inclusion criteria: 1 The age ranged from 18 to 72 years. 2 According to the diagnostic criteria of post-hepatitis B cirrhosis, serum HBsAg and/or HBV-DNA were positive for more than 6 months, and Child-Pugh grade was A-B; 3 Voluntary participants and signers of informed consent.

Exclusion criteria

Exclusion criteria: 1 Patients with liver diseases caused by other viral infections besides hepatitis B virus (HBV); 2 Patients with severe autoimmune liver disease and drug-induced liver injury; 3 Inflammatory bowel disease, irritable bowel syndrome and malignant tumors, immune system diseases or the history of immunosuppressive agents; 4 In the past month, antibiotics, gastrointestinal motility drugs and intestinal microecological regulators were used. 5 Travellers who have been to endemic diarrhea areas in the past six months; 6 Psychiatric patients; 7 Pregnant or pregnant women and lactating women; 8 Allergic constitution and allergic patients; 9 Participate in other clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
Sequencing analysis of 16S rDNA in feces;Full spectrum analysis of fecal bile acids;

Countries

China

Contacts

Public ContactJianwei Jia

Tianjin Second People's Hospital

jiaweigt@126.com+86 13920825379

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026